Agile Therapeutics

The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.
Type
Public
HQ
Princeton, US
Founded
1997
Size (employees)
18 (est)+6%
Agile Therapeutics was founded in 1997 and is headquartered in Princeton, US

Key People at Agile Therapeutics

Al Altomari

Al Altomari

President & CEO & Board ofDirectors
Scott Coiante

Scott Coiante

Chief Financial Officer
C.Gregory Arnold

C.Gregory Arnold

Vice President of Manufacturing
Robert G.Conway

Robert G.Conway

Chief Development Officer, Vice President, Operations
Marie Foegh

Marie Foegh

Chief Medical Officer, Vice President, Clinical Research and Development

Agile Therapeutics Office Locations

Agile Therapeutics has an office in Princeton
Princeton, US (HQ)
101 Poor Farm Rd

Agile Therapeutics Data and Metrics

Agile Therapeutics Financial Metrics

$, USD

Net income (FY, 2016)

(28.7 m)

EBIT (FY, 2016)

(29.7 m)

Market capitalization (23-Jun-2017)

110.6 m

Closing share price (23-Jun-2017)

3.9

Cash (31-Dec-2016)

48.8 m
Agile Therapeutics's current market capitalization is $110.6 m.
$, USDFY, 2014FY, 2015FY, 2016

R&D expense

13.4 m25.6 m20.9 m

General and administrative expense

5.2 m7.5 m8.8 m

Operating expense total

18.5 m33.1 m29.7 m

EBIT

(18.5 m)(33.1 m)(29.7 m)

Interest expense

(1.6 m)(2.1 m)(2.4 m)

Interest income

2.6 k5 k117 k

Net Income

(16.1 m)(30.3 m)(28.7 m)
$, USDFY, 2014FY, 2015FY, 2016

Cash

40.2 m34.4 m48.8 m

Current Assets

41 m38.1 m51.5 m

PP&E

12 m12.3 m12.3 m

Total Assets

54.8 m50.7 m63.9 m

Accounts Payable

2.6 m2.4 m2.1 m

Current Liabilities

9 m7.9 m10.7 m

Additional Paid-in Capital

170.4 m194.5 m235.8 m

Retained Earnings

(134.4 m)(164.7 m)(193.5 m)

Total Equity

36 m29.7 m42.3 m

Financial Leverage

1.5 x1.7 x1.5 x
$, USDFY, 2014FY, 2015FY, 2016

Net Income

(16.1 m)(30.3 m)(28.7 m)

Depreciation and Amortization

12.6 k18 k19 k

Inventories

(2.3 m)(1.2 m)922 k

Accounts Payable

2.6 m1.3 m362 k

Cash From Operating Activities

(14.5 m)(25.5 m)(23.3 m)

Purchases of PP&E

(95.7 k)(290 k)(31 k)

Cash From Investing Activities

(95.7 k)(290 k)(31 k)

Cash From Financing Activities

52.7 m20 m37.7 m

Interest Paid

1.4 m1.5 m1.5 m
Y, 2016

Financial Leverage

1.5 x

Agile Therapeutics Operating Metrics

FY, 2016

Phase III Trials

1

Phase II Trials

1

Phase I Trials

3

Patents (US)

13

Patents (foreign)

45

Agile Therapeutics Market Value History

Agile Therapeutics Company Life and Culture

You may also be interested in